Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies
暂无分享,去创建一个
Mimi Y. Kim | M. Petri | T. Porter | J. Buyon | J. Merrill | M. Guerra | C. Laskin | M. Lockshin | L. Sammaritano | D. Branch | A. Sawitzke | J. Salmon | A. Lynch | Anne M. Lynch | E. Kaplowitz | Marta M Guerra
[1] R. Gibbs,et al. The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia , 2016, American journal of reproductive immunology.
[2] M. Belfort,et al. Complement Split Products in Amniotic Fluid in Pregnancies Subsequently Developing Early-Onset Preeclampsia , 2015, Disease markers.
[3] Mimi Y. Kim,et al. Predictors of Pregnancy Outcomes in Patients With Lupus , 2015, Annals of Internal Medicine.
[4] J. Salmon,et al. Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency , 2015, The Journal of Immunology.
[5] H. Baelde,et al. Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia , 2015, Hypertension.
[6] L. Chamley,et al. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. , 2015, Autoimmunity reviews.
[7] R. Fichorova,et al. Urinary Excretion of C5b‐9 is Associated With the Anti‐Angiogenic State in Severe Preeclampsia , 2015, American journal of reproductive immunology.
[8] R. Bellomo,et al. Assessment of Cell-Cycle Arrest Biomarkers to Predict Early and Delayed Acute Kidney Injury , 2015, Disease markers.
[9] M. Kolev,et al. Complement — tapping into new sites and effector systems , 2014, Nature Reviews Immunology.
[10] K. Kalunian,et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements , 2014, Lupus Science & Medicine.
[11] V. Winn,et al. Maternal and Fetal Alternative Complement Pathway Activation in Early Severe Preeclampsia , 2014, American journal of reproductive immunology.
[12] R. Fichorova,et al. Urinary Excretion of C5b-9 in Severe Preeclampsia: Tipping the Balance of Complement Activation in Pregnancy , 2013, Hypertension.
[13] A. Tincani,et al. Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? , 2012, Rheumatology.
[14] F. Claas,et al. Preeclampsia Is Characterized by Placental Complement Dysregulation , 2012, Hypertension.
[15] S. Blackwell,et al. Autoantibody-Mediated Complement C3a Receptor Activation Contributes to the Pathogenesis of Preeclampsia , 2012, Hypertension.
[16] Mimi Y. Kim,et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. , 2012, Arthritis and rheumatism.
[17] G. Sordo,et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome , 2012, Lupus.
[18] P. Seed,et al. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome , 2012, Thrombosis and Haemostasis.
[19] S. le Cessie,et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal loss , 2011, The Journal of pathology.
[20] J. Atkinson,et al. Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort , 2011, PLoS medicine.
[21] V. D’Agati,et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. , 2011, Kidney international.
[22] J. Salmon,et al. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. , 2010, Placenta.
[23] V. Holers,et al. The interrelationship of complement‐activation fragments and angiogenesis‐related factors in early pregnancy and their association with pre‐eclampsia , 2010, BJOG : an international journal of obstetrics and gynaecology.
[24] T. Koike,et al. Complement activation in patients with primary antiphospholipid syndrome , 2008, Annals of the rheumatic diseases.
[25] J. Shamonki,et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. , 2007, American journal of obstetrics and gynecology.
[26] J. Thurman,et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction , 2006, The Journal of experimental medicine.
[27] J. Salmon,et al. TNF-α Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss1 , 2005, The Journal of Immunology.
[28] J. Lambris,et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. , 2003, The Journal of clinical investigation.
[29] Xiaowei Liu,et al. Edinburgh Research Explorer Complement C3 activation is required for antiphospholipid antibody-induced fetal loss , 2022 .
[30] B. Morgan,et al. Immunology of reproduction: Protecting the placenta , 2000, Current Biology.
[31] L. Sammaritano,et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. , 1997, Arthritis and rheumatism.
[32] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[33] D. Cunningham,et al. Decay-accelerating factor protects human trophoblast from complement-mediated attack. , 1995, Clinical immunology and immunopathology.
[34] S. Meri,et al. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. , 1993, Journal of immunology.
[35] S. Abramson,et al. Activation of the Complement Pathway: Comparison of Normal Pregnancy, Preeclampsia, and Systemic Lupus Erythematosus During Pregnancy , 1992, American journal of reproductive immunology.
[36] M. Tanner,et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. , 1990, Journal of immunology.
[37] M. Wells,et al. Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy. , 1987, Journal of reproductive immunology.
[38] Mimi Y. Kim,et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. , 2016, American journal of obstetrics and gynecology.
[39] J. Thurman,et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. , 2005, Molecular immunology.
[40] S. Abramson,et al. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. , 1992, Arthritis and rheumatism.